ClinicalTrials.gg
CompletedNCT06220123Updated Jul 22, 2025

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

A Phase 2 interventional study of SHR-2004 and Enoxaparin Sodium Injection; Rivaroxaban Tablets in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 6 open to participants now, 6 under way, 4 of them phase 3. Ovarian Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
8th of 16
225 · median 188
Started
2024
with 3 others
Phase 2
3 of 16
none open now
Registered
11th of 16
by date

Among the 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is one of 4 that started in 2024, is one of 3 in phase 2, and was the 11th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy and safety of SHR-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery.

03

Conditions studied

  • Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years old on the day of signing the form;
  2. Diagnosed as stage III-IV or recurrent ovarian cancer;
  3. Have surgical indications and no to surgery, and voluntarily undergo laparotomy or laparoscopic surgery to treat ovarian cancer;
  4. Understand the research procedures and methods, voluntarily participate in this trial, and sign the written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. The primary site of the tumor is not the ovary or there is ;
  2. A history that may increase the risk of bleeding;
  3. A history of VTE in the past or during screening, or a disease that increases thrombosis tendency such as protein C deficiency;
  4. Patients with atrial fibrillation requiring anticoagulant treatment or the use of artificial heart valves during screening;
  5. Acute coronary syndrome within 3 months;
  6. Poorly controlled hypertension before screening, and uncontrolled hypertension within 6 months severe cardiac arrhythmia;
  7. Any laboratory test indicator during screening or baseline does not meet the standards in the exclusion criteria;
  8. Have had a history of adverse reactions or allergies related to rivaroxaban or enoxaparin, such as heparin-induced thrombocytopenia;
  9. Have used any drugs prohibited other than drugs within 7 days before screening or plan to use during the study;
  10. Those who have participated in any drug intervention clinical trial within 1 month before screening, or those who are within 5 half-lives of the investigational drug at the time of screening, Whichever is longer;
  11. Those who are expected to use postoperative neuraxial analgesia;
  12. Those who are expected to use plantar vein pumps, intermittent pneumatic compression devices, electronic or mechanical muscle stimulators after surgery;
  13. Other circumstances in which the researcher believes that the subject is not suitable to participate in this trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Investigational product arm

    Drug: SHR-2004

  • Active comparator
    Positive control arm

    Drug: Enoxaparin Sodium Injection; Rivaroxaban Tablets

Interventions

  • Investigational product arm: SHR-2004

  • DrugEnoxaparin Sodium Injection; Rivaroxaban Tablets

    Drug pages: Enoxaparin sodium · Rivaroxaban

    Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint: The incidence rate of VTE from the first medication to the end of the treatment period (Day 28)

    including asymptomatic deep vein thrombosis (DVT) (confirmed by bilateral lower limb venous compression ultrasound), objectively confirmed symptomatic DVT, and objectively confirmed non-fatal. The composite endpoint of pulmonary thromboembolism (PE) and VTE-related death.

    Time frame: up to Day 28

  2. The composite endpoint incidence rate of major bleeding and clinically relevant non-major bleeding events as defined by the International Society on Thrombosis and Haemostasis (ISTH) from the first dose to the end of the treatment period

    Primary safety endpoints

    Time frame: up to Day 28

Secondary outcomes

  1. The event rate of each component of the primary efficacy endpoint

    Secondary efficacy endpoint

    Time frame: up to Day 28

  2. Secondary efficacy endpoint: The total VTE incidence rate from the first medication to the end of follow-up (D85) and the incidence rate of each component event

    including asymptomatic DVT (confirmed by bilateral lower limb venous compression color ultrasound), objectively confirmed symptomatic DVT, and objectively confirmed non-fatal. The composite endpoint of sexual PE and VTE-related death.

    Time frame: up to Day 85

  3. The event rate of each component of the primary safety endpoint

    Secondary safety endpoints

    Time frame: up to Day 28

  4. The incidence of any bleeding events (including minor bleeding events) from the first dose to the end of the treatment period

    Secondary safety endpoints

    Time frame: up to Day 28

  5. The composite endpoint incidence rate and each component event rate of major bleeding and clinically relevant non-major bleeding events that meet the definition of ISTH from the first medication to the end of follow-up

    Secondary safety endpoints

    Time frame: up to Day 85

  6. The incidence of any bleeding events (including minor bleeding events) from the first dose to the end of follow-up

    Secondary safety endpoints

    Time frame: up to Day 85

  7. The incidence and severity of adverse events.

    Secondary safety endpoints

    Time frame: up to Day 85

07

Study locations

1 site
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Dec 2024, 10 months.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 10 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2024
First posted
Jan 23, 2024
StartActual
Feb 16, 2024
Primary completionActual
Dec 31, 2024
CompletionActual
Dec 31, 2024
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06220123
Responsible party
Sponsor
First posted
Jan 23, 2024
Start date
Feb 16, 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Jul 22, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-2004

Start the discussion